Literature DB >> 9575153

Serine 13 is the site of mitotic phosphorylation of human thymidine kinase.

Z F Chang1, D Y Huang, L M Chi.   

Abstract

It has been reported that the polypeptide of thymidine kinase type 1 (TK1) from human and mouse cells can be modified by phosphorylation. Our laboratory has further shown that the level of human TK phosphorylation increases during mitotic arrest in different cell types (Chang, Z.-F., Huang, D.-Y., and Hsue, N.-C. (1994) J. Biol. Chem. 269:21249-21254). In the present study, we demonstrated that a mutation converting Ser13 to Ala abolished the mitotic phosphorylation of native TK1 expressed in Ltk- cells. Furthermore, we expressed recombinant proteins of wild-type and mutated human TK1 with fused FLAG epitope in HeLa cells, and confirmed the occurrence of mitotic phosphorylation on Ser13 of hTK1. By using an in vitro phosphorylation assay, it was shown that wild-type hTK1, but not mutant TK1(Ala13), could serve as a good substrate for Cdc2 or Cdk2 kinase. Coexpression of p21(waf1/cip1), which is a universal inhibitor of Cdk kinases, in Ltk- fibroblasts also suppressed mitotic phosphorylation of hTK1 expressed in this cell line. Thus, Cdc2 or related kinase(s) is probably involved in mitotic phosphorylation on Ser13 of the hTK1 polypeptide. We also found that mutation on Ser13 did not affect the functional activity of hTK1. As the sequences around Ser13 are highly conserved in vertebrate TK1s, we speculate that phosphorylation of Ser13 may play a role in the regulation of TK1 expression in the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9575153     DOI: 10.1074/jbc.273.20.12095

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.

Authors:  Sara Rapic; Christel Vangestel; Jeroen Verhaeghe; David Thomae; Patrick Pauwels; Tim Van den Wyngaert; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

2.  Degradation of human thymidine kinase is dependent on serine-13 phosphorylation: involvement of the SCF-mediated pathway.

Authors:  Po-Yuan Ke; Che-Chuan Yang; I-Chun Tsai; Zee-Fen Chang
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

3.  Binding of ATP to TK1-like enzymes is associated with a conformational change in the quaternary structure.

Authors:  Dario Segura-Peña; Stefan Lutz; Christian Monnerjahn; Manfred Konrad; Arnon Lavie
Journal:  J Mol Biol       Date:  2007-03-15       Impact factor: 5.469

4.  Interaction of human thymidine kinase 1 with p21(Waf1).

Authors:  D Y Huang; Z F Chang
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

5.  The future of imaging: developing the tools for monitoring response to therapy in oncology: the 2009 Sir James MacKenzie Davidson Memorial lecture.

Authors:  E O Aboagye
Journal:  Br J Radiol       Date:  2010-08-17       Impact factor: 3.039

6.  Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability.

Authors:  Po-Yuan Ke; Yuan-Yeh Kuo; Chuan-Mei Hu; Zee-Fen Chang
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

7.  Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway.

Authors:  Po-Yuan Ke; Zee-Fen Chang
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

8.  Phosphorylation status of thymidine kinase 1 following antiproliferative drug treatment mediates 3'-deoxy-3'-[18F]-fluorothymidine cellular retention.

Authors:  Roberta Sala; Quang-Dé Nguyen; Chirag B K Patel; David Mann; Joachim H G Steinke; Ramon Vilar; Eric O Aboagye
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

Review 9.  Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.

Authors:  Chad R Irwin; Mary M Hitt; David H Evans
Journal:  Front Oncol       Date:  2017-09-26       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.